Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Retraction: Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function.

Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V.

Cancer Res. 2019 Apr 15;79(8):2085. doi: 10.1158/0008-5472.CAN-19-0560. No abstract available.

PMID:
30987981
2.

Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.

Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M.

Oncogene. 2006 Jan 19;25(3):359-69.

PMID:
16170349
3.

The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis.

Bar J, Lukaschuk N, Zalcenstein A, Wilder S, Seger R, Oren M.

Cell Death Differ. 2005 Dec;12(12):1578-87. Epub 2005 Jun 3.

4.

Transactivation of the EGR1 gene contributes to mutant p53 gain of function.

Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V.

Cancer Res. 2004 Nov 15;64(22):8318-27. Retraction in: Cancer Res. 2019 Apr 15;79(8):2085.

5.

Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.

Zalcenstein A, Stambolsky P, Weisz L, Müller M, Wallach D, Goncharov TM, Krammer PH, Rotter V, Oren M.

Oncogene. 2003 Aug 28;22(36):5667-76.

PMID:
12944915
6.
7.

The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor.

Elkeles A, Juven-Gershon T, Israeli D, Wilder S, Zalcenstein A, Oren M.

Mol Cell Biol. 1999 Apr;19(4):2594-600.

Supplemental Content

Loading ...
Support Center